Home |
Current Issue |
Past Issues |
Audio/Video |
CME |
Collections |
In the Clinic |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 June 1994 | Volume 120 Issue 12 | Pages 977-981
Objective: To determine whether a preexisting Helicobacter pylori infection increases the risk for developing duodenal or gastric ulcer.
Design: A nested casecontrol study based on a cohort of 5443 Japanese-American men who had a physical examination and a phlebotomy from 1967 to 1970.
Setting: All 10 general hospitals on the Hawaiian island of Oahu.
Patients: 150 patients with gastric ulcer and 65 patients with duodenal ulcer identified in the cohort of study participants after a hospital surveillance period of more than 20 years.
Measurements: Stored serum specimens from patients and from matched controls were tested for the presence of serum IgG antibody to H. pylori using enzyme-linked immunosorbent assay.
Results: 93% of the 150 patients with gastric ulcer and 78% of the matched controls had a positive antibody level for H. pylori-specific IgG, yielding an odds ratio of 3.2 (95% CI, 1.6 to 6.5). For duodenal ulcer, 92% of the 65 patients and 78% of the matched controls had a positive test result, yielding an odds ratio of 4.0 (CI, 1.1 to 14.2). As the level of antibody to H. pylori increased, a statistically significant increase was noted in the risk for gastric and duodenal ulcer. The association with H. pylori infection was statistically significant for both types of ulcer, even when the diagnosis was made 10 or more years after the serum sample had been obtained.
Conclusion: Preexisting H. pylori infection increases the risk for subsequent development of either duodenal or gastric ulcer disease.
None of the previous studies evaluated patients with duodenal or gastric ulcers before they were diagnosed or hospitalized with their disease. The usual temporal sequence is that patients with peptic ulcer disease are examined to detect H. pylori infection at the time the diagnosis is made or after they have had treatment to eradicate the organism. Consequently, peptic ulceration could possibly predispose persons to colonization by H. pylori [9].
We did a prospective study in a large population-based cohort using serum specimens that were obtained from study participants before they were diagnosed with peptic ulcer. We tried to determine whether H. pylori infection, as shown by the presence of specific IgG antibodies, is a risk factor for the subsequent development of either duodenal or gastric ulceration.
Japanese-American men born from 1900 to 1919, who were identified by the Honolulu Heart Program in 1965 by using the comprehensive 1942 Selective Service draft registration files [10], composed the study population. Of 11 148 eligible men, 8006 (72%) were interviewed and examined from 1965 to 1968, 180 (2%) died before they could be examined, and 2962 (26%) did not participate in the program. Study participants ranged in age from 45 to 68 years. The data collected included birthplace, marital status, history of alcohol use, blood pressure, and body mass index (the weight in kilograms divided by the square of the height in meters). Serum cholesterol values were determined by the Auto Analyzer N-24A method, and serum glucose values were determined by the Auto Analyzer N-2B method 1 hour after a 50-g glucose load had been given [11].
A total of 7498 (94%) men returned for a second examination between 1967 and 1970, and a serum specimen was obtained at this time. Serum specimens for a 20% random sample of the men were sent to the U.S. Public Health Service Hospital in San Francisco, whereas specimens for the remaining 5924 men were stored at 20°C at the study site. Four hundred eighty-one patients with previous gastrectomy or a previous diagnosis of peptic ulcer disease were excluded from the study. The average age of the remaining 5443 patients at the time of their second examination was 56.6 years.
Two hundred fifty-eight patients were hospitalized with peptic ulcer disease from 1968 to 1989. One hundred sixty (62%) patients had their diagnosis confirmed by examination of tissue obtained by either surgery or biopsy, 36 (14%) were diagnosed by radiologic examination, and 62 (24%) were clinically diagnosed based on the endoscopic or surgical report of the presence of an ulcer.
One hundred sixty-nine incident patients had gastric ulcer, 73 had duodenal ulcer, and 16 had gastric and duodenal ulcers. Seventeen of the 169 patients with gastric ulcer, 6 of the 73 patients with duodenal ulcer, and 2 of the 16 patients with gastric and duodenal ulcers were removed from study because they had an insufficient amount of serum in the freezer repository. ARTICLE
Helicobacter pylori Infection and the Risk for Duodenal and Gastric Ulceration
Infection with Helicobacter pylori probably increases the risk for developing duodenal and gastric ulcer disease. Previous studies have shown that 75% to 100% of patients with duodenal ulcer and 35% to 86% of patients with gastric ulcer have evidence of an H. pylori infection [1]. The finding that eradication of H. pylori in patients with duodenal ulcer is associated with a statistically significant decrease in the recurrence rate of the disease further supports the association [2-5]. However, these observations may just reflect the frequent coexistence of duodenal ulcer with antral gastritis [6], which has been shown to be caused by H. pylori [7, 8]. Wormsley [9] has noted that the Henle-Koch postulates have not been satisfied for causation of duodenal ulcer by H. pylori because the organism has not been shown to produce the disease. The evidence is weaker that H. pylori causes gastric ulcer because only a single study with 26 patients has shown that antimicrobial therapy directed against H. pylori decreased the gastric ulcer recurrence rate [5].
Methods
![]()
Top
Methods
Statistical Analysis
Results
Discussion
Author & Article Info
References
Study Population
Surveillance Methods
![]()
Surveillance of the cohort to identify incident patients with peptic ulcer was done by a continuous review of discharge records of all general hospitals on Oahu. Based on a 19-year follow-up survey of the study patients from the time of their examination in 1965 to 1968, only 1.3% of the men could not be located on Oahu. Thus, surveillance was nearly complete.
Selection of Controls
![]()
Each of the remaining patients was matched with one control from the study cohort based on age at examination (47 to 70 years) and date of serum collection. If a potential control had a diagnosis of gastric cancer before or after the serum was obtained, he was excluded from the study. As a consequence, 160 patients (3.1%) were removed from the control pool of 5185 men because of the reported association between H. pylori infection and gastric cancer [12, 13]. Of the remaining 5025 men, 336 (6.7%) were excluded because they previously had cardiovascular disease or other cancer, and 1532 (30.5%) were excluded because they were diagnosed with cardiovascular disease or other cancer after their serum collection. This exclusion was done because the serum specimens from these patients are going to be used for other studies. A total of 3157 patients remained in the pool of controls from which 233 (7.4%) were matched to incident case-patients with peptic ulcer. Each control participant was alive at the time of hospitalization of the matched case-patient, so that death was not a competing factor.
Serologic Testing
![]()
The presence of serum IgG antibodies to H. pylori was determined by enzyme-linked immunosorbent assay (ELISA), using the Pyloristat kit (Whittaker Bioproducts, Inc., Walkersville, Maryland). As validated by the manufacturer, the results of this assay closely mirror those of a previously described IgG ELISA [13-18]. In brief, serum specimens from patients were diluted 1:20 for use in the kit, and IgG levels of sera were determined according to the manufacturer's instructions. The serum specimens were coded so that the laboratory technician could not distinguish case-patients from controls. A ratio of 1.00 or greater was considered positive, a ratio of less than 0.80 was considered negative, and a ratio of 0.80 to 0.99 was considered equivocal, as calibrated in the kit. Two patients with gastric ulcer and two patients with duodenal ulcer or their controls had equivocal values, so they were excluded from the study.
Statistical Analysis
![]()
Top
Methods
Statistical Analysis
Results
Discussion
Author & Article Info
References
A matched casecontrol study design was used to identify the patients and controls for serum tests. As a result, odds ratios, based on the results of the H. pylori IgG antibody test, were determined using conditional logistic regression methods [19]. When odds ratios were indeterminable, approximate confidence intervals (CIs) were determined by the method of Breslow and Day [19]. Tests for trend in the logit of risk were derived from conditional logistic regression models by using grouped H. pylori test results (coded as 1, 2, 3, and 4). All conditional logistic regression models were fitted using iterative maximum likelihood methods and a special application of the proportional hazards regression model [20].
Results
![]()
Top
Methods
Statistical Analysis
Results
Discussion
Author & Article Info
References
The characteristics of the 229 patients with peptic ulcer and of their matched controls are presented in Table 1. The two groups of men were similar with respect to demographic characteristics and laboratory values.
|
The mean age at diagnosis was 67.5 years (range, 52.7 to 87.2 years) for the 150 patients with gastric ulcer, 64.5 years (49.4 to 80.0 years) for the 65 patients with duodenal ulcer, and 63.5 years (52.4 to 83.1 years) for the 14 patients with gastric and duodenal ulcers.
Table 2 shows the association between the H. pylori test result and peptic ulcer by specific type. Ninety-three percent (139 of 150) of the patients with gastric ulcer and 78% (117 of 150) of the matched controls had a positive H. pylori-specific IgG antibody level, yielding an odds ratio of 3.2 (P = 0.001). (The odds ratio is determined by dividing 32 ± pairs by 10 -/+ pairs.) Ninety-two percent of the case-patients with duodenal ulcer and 78% of the matched controls had a positive test result, yielding an odds ratio of 4.0 (P = 0.03). If a patient had either a gastric or duodenal ulcer, then the odds ratio was 3.4 (P = 0.0001). Only 14 patients had both gastric and duodenal ulcers. The odds ratio was 1.3 (P > 0.2), based on these patients.
|
Because some of the hospitalized patients with peptic ulcer may have developed their ulcers after the use of adrenocorticosteroids or nonsteroidal anti-inflammatory drugs, we systematically reviewed the hospital records of the patients. A similar review could not be done for the controls because they were not hospitalized. We found that 18 of the 150 patients with gastric ulcer and 9 of the 65 patients with duodenal ulcer had taken these medications at the time of hospitalization. If these patients and their matched controls were excluded, the odds ratio would have been 3.3 (95% CI, 1.6 to 7.0) for gastric ulcer, 3.3 (CI, 0.9 to 12.1) for duodenal ulcer, and 3.3 (CI, 1.7 to 6.4) for either gastric or duodenal ulcer.
Of the 215 patients with either gastric or duodenal ulcer, 100 also had a hospital-based diagnosis of cardiovascular disease or cancer. If these patients were excluded from the study, as were controls with these diseases, 115 patients with gastric or duodenal ulcer would have remained in the study. Ninety-four percent of these case-patients and 77% of their controls had a positive test result for H. pylori antibody. The odds ratio for peptic ulcer was 4.3 (CI, 1.8 to 10.5) in this group of patients.
When the patients with gastric ulcer who had positive antibody results were separated into tertile groupings, based on the distribution of antibody levels among men who were controls, a trend (P < 0.001) was noted in the odds ratios (Table 3). The same analysis was done for the patients with duodenal ulcer Table 4 and a linear trend was also found (P = 0.014). The highest tertile group had an odds ratio of 6.8 when compared with patients who had a negative test result for H. pylori antibody.
|
|
The median and mean time intervals from phlebotomy to hospitalization were 10.7 and 10.2 years, respectively, for the 150 patients with gastric ulcer and were 8.5 and 9.0 years, respectively, for the 65 patients with duodenal ulcer. We did an analysis to determine whether the association of antibody positivity with ulcer was affected as the time interval from phlebotomy to hospitalization increased (Table 5). Patients diagnosed 0 to 9 years after phlebotomy or 10 or more years after phlebotomy had a statistically significant increased risk for gastric ulcer. For duodenal ulcer, a statistically significant association was observed mainly for patients hospitalized 10 or more years after phlebotomy.
|
Discussion
|
|---|
|
|
|---|
First, this study identified hospitalized patients with peptic ulcer but did not identify nonhospitalized patients who were diagnosed during the surveillance period. Because of practical considerations, surveillance was limited to only the review of hospital records of study participants and did not include other sources of medical records. If nonhospitalized patients with peptic ulcer are included in the control group and if a positive association with H. pylori infection also exists among these patients with less complicated disease, then the findings of our study underestimate the strength of the association between peptic ulcer disease and previous infection with H. pylori.
Second, some of the patients may have been diagnosed with peptic ulcer before they were hospitalized with their condition. This would likely apply more to patients with duodenal ulcer than to those with gastric ulcer. However, each hospital record was carefully reviewed and the date of earliest diagnosis of peptic ulcer, even without hospitalization, was recorded. As a result, 481 patients (170 patients with peptic ulcer who did not have gastrectomy and 311 who had had a gastrectomy) were excluded from the study because their condition existed before study entry. This is standard procedure for cohort studies, which identify characteristics that precede the appearance of the disease under investigation [21].
Third, we could not completely assess the effects of the use of adrenocorticosteroids or nonsteroidal anti-inflammatory drugs on the diagnosis of peptic ulcer in this cohort because information on the use of these medications was not available for controls. However, exclusion of those patients whose hospital records indicated that they had recently used the medications did not substantially change the results shown in Table 2. These findings are consistent with the observation that the use of nonsteroidal anti-inflammatory drugs does not increase susceptibility to H. pylori infection [22].
Lastly, although 37% of the potential controls in our study were excluded because of cancer or cardiovascular disease, their exclusion did not appreciably affect the findings. Some of the serum specimens had been thawed previously for use in other studies, but we reported previously that multiple cycles of freezing and thawing do not affect the results of H. pylori serologic determinations [23].
More patients had gastric ulcer than had duodenal ulcer in this investigation. This predominance of gastric ulceration among Japanese-Americans has been shown in an earlier study [24], which also reported that the average age at diagnosis was higher among patients with gastric ulcer (53.8 years) than among those with duodenal ulcer (48.3 years). This difference would favor the diagnosis of more patients with gastric ulcer in our study because the average age of the patients at study entry was 56.6 years (age range, 47 to 70 years).
Our finding that H. pylori infection preceded the diagnosis of peptic ulcer is strengthened by the observation that patients hospitalized 10 or more years after phlebotomy still showed a statistically significant association (Table 5). This supports the view that infection with H. pylori contributes to the clinical manifestation of peptic ulcer and makes it less likely that ulceration predisposes patients to colonization by H. pylori. As suggested by Rabeneck and Ransohoff [25], establishing that H. pylori infection precedes duodenal ulcer makes it less plausible that H. pylori is a commensal organism. Based on our findings, 44% of the total risk for hospitalization with either gastric or duodenal ulcer can be attributed to a previous H. pylori infection [26].
An increase was noted in the risk for peptic ulcer with increasing antibody levels for H. pylori, especially for duodenal ulcer. In vitro studies indicate that soluble H. pylori products recruit [27] and activate macrophages [28]. The height of the IgG immune response may be related to the extent of inflammation in the gastric mucosa or of metaplastic gastric epithelium in the duodenum [29]; thus, the intensity of inflammation might contribute to the risk for ulcer development. In an analysis of gastric cancer in the same cohort of men [13], high antibody levels also were associated with increased risk; thus, the results of these two studies are parallel.
Despite the evidence that an H. pylori infection precedes the diagnosis of peptic ulcer, we found that 77% of the population-based controls in this study also were infected with this organism. Although 12.5% of the 5924 participants in the study have been diagnosed with peptic ulcer disease (481 before study entry and 258 after study entry), most of the H. pylori-infected participants will probably never develop peptic ulcer. These data indicate that other factors in addition to H. pylori infection have an important role in the development of peptic ulcer. Duodenal ulceration may ultimately depend on the synergy between H. pylori infection and the presence of gastric metaplasia in the duodenum [30]. The organism does not colonize the small intestinal mucosa but has been identified in areas of gastric metaplasia within the duodenum [31, 32].
Helicobacter pylori is the major causative agent for chronic superficial (antral and fundic) gastritis [7, 8]. The presence of this type of gastritis is strongly associated with the presence of duodenal and gastric ulcers [33]. In a recent prospective study in Finland, Sipponen and colleagues [34] found that the evidence of chronic gastritis in biopsy specimens was associated with a 14-fold increase in the risk for peptic ulcer during the next decade. That study provides further evidence that pre-existing H. pylori infection is a risk factor for peptic ulceration through its effects leading to chronic gastritis.
Our study is consistent with other reports [2-5, 7, 35] and shows for the first time that H. pylori infection is associated with an increased risk for the subsequent development of peptic ulcer disease. This association is probably mediated at least in part by the chronic inflammation induced by H. pylori [36]. Whether this process is attributable to direct bacterial injury [37, 38], facilitation of mucosal injury by host aggressive factors [33], host immune and inflammatory response to the organisms [27, 28], or a combination [36] remains to be determined.
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Taylor DN, Blaser MJ. The epidemiology of Helicobacter pylori infection. Epidemiol Rev. 1991; 13:42-59.
2. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988; 2:1437-42.
3. Coghlan JG, Gilligan D, Humphries H, McKenna D, Dooley C, Sweeney E, et al.Campylobacter pylori and recurrence of duodenal ulcersa 12-month follow-up study. Lancet. 1987; 2:1109-11.
4. Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990; 335:1233-5.
5. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992; 116:705-8.
6. Dooley CP, Cohen H. The clinical significance of Campylobacter pylori. Ann Intern Med. 1988; 108:70-9.
7. Peterson WL.Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991; 324:1043-8.
8. Blaser MJ.Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis. 1990; 161:626-33.
9. Wormsley KG.Campylobacter pylori and ulcer diseasea causal connection? Scand J Gastroenterol. 1989; 160:53-8.
10. Worth RM, Kagan A. Ascertainment of men of Japanese ancestry in Hawaii through World War II Selective Service registration. J Chronic Dis. 1970; 23:389-97.
11. Kagan A, Harris BR, Winkelstein W Jr, Johnson KG, Kato H, Syme SL, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chronic Dis. 1974; 27:345-64.
12. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al.Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127-31.
13. Nomura A, Stemmermann GN, Chyou P-H, Kato I, Perez-Perez GI, Blaser MJ.Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325: 1132-6.
14. Dooley CP, Cohen H, Fitzgibbons PL, Bauer M, Appleman MD, Perez-Perez GI, et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med. 1989; 321:1562-6.
15. Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ.Campylobacter pylori antibodies in humans. Ann Intern Med. 1988; 109:11-7.
16. Drumm B, Perez-Perez GI, Blaser MJ, Sherman PM. Intrafamilial clustering of Helicobacter pylori infection. N Engl J Med. 1990; 322: 359-63.
17. Glassman MS, Dallal S, Berezin SH, Bostwick HE, Newman L, Perez-Perez GI, et al.Helicobacter pylori-related gastroduodenal disease in children. Diagnostic utility of enzyme-linked immunosorbent assay. Dig Dis Sci. 1990; 35:993-7.
18. Strauss RM, Wang TC, Kelsey PB, Compton CC, Ferraro M-J, Perez-Perez G, et al. Association of Helicobacter pylori infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. Am J Med. 1990; 89:464-9.
19. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol. 1. The Analysis of Case-control Studies. Lyon, France: International Agency for Research on Cancer; 1980:164-6, 247-76. (IARC scientific publication no. 32).
20. Harrell FE Jr. The PHGLM procedure. In: Joyner SP, ed. SUGI Supplemental Library User's Guide. Cary, NC: SAS Institute; 1983; 267-94.
21. MacMahon B, Pugh TF. Epidemiology: Principles and Methods. Boston: Little, Brown; 1970:207.
22. Graham DY, Lidsky MD, Cox AM, Evans DJ Jr, Evans DG, Alpert L, et al. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology. 1991; 100:1653-7.
23. Blaser MJ, Perez-Perez GI, Lindenbaum J, Schneidman D, Van Deventer G, Marin-Sorensen M, et al. Association of infection due to Helicobacter pylori with specific upper gastrointestinal pathology. Rev Infect Dis. 1991; 13(Suppl 8):S704-8.
24. Stemmermann GN, Hayashi T. Intestinal metaplasia of the gastric mucosa: a gross and microscopic study of its distribution in various disease states. J Natl Cancer Inst. 1968; 41:627-34.
25. Rabeneck L, Ransohoff DF. Is Helicobacter pylori a cause of duodenal ulcer? A methodologic critique of current evidence. Am J Med. 1991; 91:566-72.
26. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA: Lifetime Learning Publications; 1982.
27. Mai UE, Perez-Perez GI, Allen JB, Wahl SM, Blaser MJ, Smith PD. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. J Exp Med. 1992; 175:517-25.
28. Mai UE, Perez-Perez GI, Wahl LM, Wahl SM, Blaser MJ, Smith PD. Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism. J Clin Invest. 1991; 87:894-900.
29. Imai K, Sugiyama T, Takayama Y, Yoshida H, Yabana T, Yachi A, et al. Immunological investigation of Helicobacter pylori infection in gastric mucosal lesions. In: Takemoto T, Kawai K, Shimoyama T, Kimura K, eds. Helicobacter pylori and Gastro-Duodenal Diseases. Vol. 3. Tokyo: Iji Publishing; 1991:26-30.
30. Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric campylobacter infection and gastroduodenal disease. Med J Aust. 1985; 142:439-43.
31. Wyatt JI, Rathbone BJ, Dixon MF, Heatley RV.Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis. J Clin Pathol. 1987; 40:841-8.
32. Steer HW. Surface morphology of the gastroduodenal mucosa in duodenal ulceration. Gut. 1984; 25:1203-10.
33. Sipponen P, Seppala K, Aarynen M, Helske T, Kettunen P. Chronic gastritis and gastroduodenal ulcer: a case control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis. Gut. 1989; 30:922-9.
34. Sipponen P, Varis K, Fraki O, Korri UM, Seppaa K, Siurala M. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scand J Gastroenterol. 1990; 25:966-73.
35. Hentschel E, Brandstatter G, Dragoisics B, Hirschl AM, Nemec H, Schutze K, et al. Effect of ranitidine and amoxycillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993; 328:308-12.
36. Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology. 1992; 102:720-7.
37. Figura N, Guglielmetti P, Rossolini A, Barberi A, Cusi G, Musmanno RA, et al. Cytotoxic production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Microbiol. 1989; 27:225-6.
38. Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem. 1992; 267: 10570-5.
Related articles in Annals:
This article has been cited by other articles:
![]() |
M. J Blaser, Y. Chen, and J. Reibman Does Helicobacter pylori protect against asthma and allergy? Gut, May 1, 2008; 57(5): 561 - 567. [Full Text] [PDF] |
||||
![]() |
E. T. Ryan, S. L. Aquino, and R. L. Kradin Case 29-2007 -- A 51-Year-Old Man with Gastric Cancer and Lung Nodules N. Engl. J. Med., September 20, 2007; 357(12): 1239 - 1246. [Full Text] [PDF] |
||||
![]() |
M. H. Pillinger, N. Marjanovic, S.-Y. Kim, Y.-C. Lee, J. U. Scher, J. Roper, A. M. Abeles, P. I. Izmirly, M. Axelrod, M. Y. Pillinger, et al. Helicobacter pylori Stimulates Gastric Epithelial Cell MMP-1 Secretion via CagA-dependent and -independent ERK Activation J. Biol. Chem., June 29, 2007; 282(26): 18722 - 18731. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ghose, G. I. Perez-Perez, V. J. Torres, M. Crosatti, A. Nomura, R. M. Peek Jr., T. L. Cover, F. Francois, and M. J. Blaser Serological Assays for Identification of Human Gastric Colonization by Helicobacter pylori Strains Expressing VacA m1 or m2 Clin. Vaccine Immunol., April 1, 2007; 14(4): 442 - 450. [Abstract] [Full Text] [PDF] |
||||
![]() |
J R Bebb, L Leach, A Zaitoun, N Hand, D P Letley, R Thomas, and J C Atherton Effects of Helicobacter pylori on the cadherin-catenin complex J. Clin. Pathol., December 1, 2006; 59(12): 1261 - 1266. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Kamoda, K. Anzai, J.-i. Mizoguchi, M. Shiojiri, T. Yanagi, T. Nishino, and S. Kamiya In Vitro Activity of a Novel Antimicrobial Agent, TG44, for Treatment of Helicobacter pylori Infection. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3062 - 3069. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Huang, J. Kang, and M. J. Blaser Antimutator Role of the DNA Glycosylase mutY Gene in Helicobacter pylori. J. Bacteriol., September 1, 2006; 188(17): 6224 - 6234. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Kusters, A. H. M. van Vliet, and E. J. Kuipers Pathogenesis of Helicobacter pylori Infection Clin. Microbiol. Rev., July 1, 2006; 19(3): 449 - 490. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bhat, J. Gaensbauer, R. M. Peek, K. Bloch, K.-T. Tham, M. J. Blaser, and G. Perez-Perez Local and Systemic Immune and Inflammatory Responses to Helicobacter pylori Strains Clin. Vaccine Immunol., December 1, 2005; 12(12): 1393 - 1400. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Chui, T. M. Clay, H. K. Lyerly, and M. A. Morse The Development of Therapeutic and Preventive Vaccines for Gastric Cancer and Helicobacter pylori Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1883 - 1889. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ghose, G. I. Perez-Perez, L. J. van Doorn, M. G. Dominguez-Bello, and M. J. Blaser High Frequency of Gastric Colonization with Multiple Helicobacter pylori Strains in Venezuelan Subjects J. Clin. Microbiol., June 1, 2005; 43(6): 2635 - 2641. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Salaun, B. Linz, S. Suerbaum, and N. J. Saunders The diversity within an expanded and redefined repertoire of phase-variable genes in Helicobacter pylori Microbiology, April 1, 2004; 150(4): 817 - 830. [Abstract] [Full Text] [PDF] |
||||
![]() |
J R Bebb, D P Letley, R J Thomas, F Aviles, H M Collins, S A Watson, N M Hand, A Zaitoun, and J C Atherton Helicobacter pylori upregulates matrilysin (MMP-7) in epithelial cells in vivo and in vitro in a Cag dependent manner Gut, October 1, 2003; 52(10): 1408 - 1413. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Al-Soud, M. Bennedsen, S. L. W. On, I.-S. Ouis, P. Vandamme, H.-O. Nilsson, A. Ljungh, and T. Wadstrom Assessment of PCR-DGGE for the identification of diverse Helicobacter species, and application to faecal samples from zoo animals to determine Helicobacter prevalence J. Med. Microbiol., September 1, 2003; 52(9): 765 - 771. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Risch Etiology of Pancreatic Cancer, With a Hypothesis Concerning the Role of N-Nitroso Compounds and Excess Gastric Acidity J Natl Cancer Inst, July 2, 2003; 95(13): 948 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Bebb, D. P. Letley, J. L. Rhead, and J. C. Atherton Helicobacter pylori Supernatants Cause Epithelial Cytoskeletal Disruption That Is Bacterial Strain and Epithelial Cell Line Dependent but Not Toxin VacA Dependent Infect. Immun., June 1, 2003; 71(6): 3623 - 3627. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lundin, C. Nilsson, M. Gerhard, D. I. Andersson, M. Krabbe, and L. Engstrand The NudA Protein in the Gastric Pathogen Helicobacter pylori Is an Ubiquitous and Constitutively Expressed Dinucleoside Polyphosphate Hydrolase J. Biol. Chem., March 28, 2003; 278(14): 12574 - 12578. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Hill, G. Gridley, S. Cnattingius, L. Mellemkjaer, M. Linet, H.-O. Adami, J. H. Olsen, O. Nyren, and J. F. Fraumeni Jr Mortality and Cancer Incidence Among Individuals With Down Syndrome Arch Intern Med, March 24, 2003; 163(6): 705 - 711. [Abstract] [Full Text] [PDF] |
||||
![]() |
N L A Arents, J C Thijs, and J H Kleibeuker A rational approach to uninvestigated dyspepsia in primary care: review of the literature Postgrad. Med. J., December 1, 2002; 78(926): 707 - 716. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Delany, G. Spohn, R. Rappuoli, and V. Scarlato Growth Phase-Dependent Regulation of Target Gene Promoters for Binding of the Essential Orphan Response Regulator HP1043 of Helicobacter pylori J. Bacteriol., September 1, 2002; 184(17): 4800 - 4810. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Xu, R. D. Morgan, R. J. Roberts, S. Y. Xu, L. J. van Doorn, J. P. Donahue, G. G. Miller, and M. J. Blaser Functional analysis of iceA1, a CATG-recognizing restriction endonuclease gene in Helicobacter pylori Nucleic Acids Res., September 1, 2002; 30(17): 3839 - 3847. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Y. Nomura, G. I. Perez-Perez, J. Lee, G. Stemmermann, and M. J. Blaser Relation between Helicobacter pylori cagA Status and Risk of Peptic Ulcer Disease Am. J. Epidemiol., June 1, 2002; 155(11): 1054 - 1059. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-O. Nilsson, J. Blom, W. A. Al-Soud, A. Ljungh, L. P. Andersen, and T. Wadstrom Effect of Cold Starvation, Acid Stress, and Nutrients on Metabolic Activity of Helicobacter pylori Appl. Envir. Microbiol., January 1, 2002; 68(1): 11 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kanamaru, Y. Nakano, Y. Toyoda, K.-I. Miyagawa, M. Tada, T. Kaisho, and M. Nakao In Vitro and In Vivo Antibacterial Activities of TAK-083, an Agent for Treatment of Helicobacter pylori Infection Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2455 - 2459. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Solnick and D. B. Schauer Emergence of Diverse Helicobacter Species in the Pathogenesis of Gastric and Enterohepatic Diseases Clin. Microbiol. Rev., January 1, 2001; 14(1): 59 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rosenstock, T. Jorgensen, L. Andersen, and O. Bonnevie Seroconversion and seroreversion in IgG antibodies to Helicobacter pylori: a serology based prospective cohort study J. Epidemiol. Community Health, June 1, 2000; 54(6): 444 - 450. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gdalevich, D. Cohen, I. Ashkenazi, D. Mimouni, O. Shpilberg, and J. D Kark Helicobacter pylori infection and subsequent peptic duodenal disease among young adults Int. J. Epidemiol., June 1, 2000; 29(3): 592 - 595. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. O'Gara, D. J. Hill, and D. J. Maslin Activities of Garlic Oil, Garlic Powder, and Their Diallyl Constituents against Helicobacter pylori Appl. Envir. Microbiol., May 1, 2000; 66(5): 2269 - 2273. [Abstract] [Full Text] |
||||
![]() |
J. Danesh, M. Lawrence, M. Murphy, S. Roberts, and R. Collins Systematic Review of the Epidemiological Evidence on Helicobacter pylori Infection and Nonulcer or Uninvestigated Dyspepsia Arch Intern Med, April 24, 2000; 160(8): 1192 - 1198. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Worku, R. L. Sidebotham, M. M. Walker, T. Keshavarz, and Q. N. Karim The relationship between Helicobacter pylori motility, morphology and phase of growth: implications for gastric colonization and pathology Microbiology, October 1, 1999; 145(10): 2803 - 2811. [Abstract] [Full Text] |
||||
![]() |
|